URGN
UroGen Pharma Ltd
41.40$
+0.3%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +12.8% | -20.2% | +16.3% | +15.4% | -2.5% | -17.5% | +19.6% | +13.5% | +37.7% | +34.7% | +42.2% | – | |
| – | -3.4% | -24.4% | +29.0% | +10.0% | +0.7% | -5.7% | +52.4% | -7.7% | +0.3% | +25.8% | +58.8% | – | |
| – | +14.9% | -19.7% | +15.0% | +16.0% | -2.9% | -18.9% | +15.3% | +17.1% | +42.7% | +35.5% | +40.7% | – | |
| – | +10.5% | +37.1% | -0.6% | -26.3% | +31.2% | +33.4% | -4.8% | -25.9% | +2.2% | +9.0% | +11.1% | – | |
| – | +12.9% | +11.2% | +10.1% | -3.7% | +20.4% | +0.3% | +23.5% | -13.0% | +4.7% | +30.8% | -5.9% | – | |
| – | +12.1% | +19.4% | +6.2% | -11.4% | +23.5% | +10.2% | +13.3% | -16.9% | +4.0% | +25.0% | -2.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -6.0% | -31.8% | +41.4% | -21.4% | +43.0% | +4.5% | +115.7% | -8.9% | +62.7% | -33.2% | -43.8% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -98.6% | -29.6% | +139.5% | +2,811.0% | -85.2% | +158.9% | -203.8% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.